Tempus AI Stock Jumped 44% — Then Insiders Dumped $2.6M. Here's Why That Might Be a Signal.

Tempus AI (NASDAQ: TEM) is making headlines after its stock surged roughly 44% on two catalysts: the acquisition of genetic testing leader Ambry Genetics for $600 million and high-profile political and institutional buying. The deal, structured as $375 million in cash and $225 million in shares, aligns with Tempus's strategy to use diagnostics and AI data to improve healthcare. CEO Eric Lefkofsky stated the acquisition 'complements our strategy of leveraging diagnostics and data to drive innovation, further strengthening our ability to deliver cutting-edge solutions to clinicians, patients, and life sciences companies.' The move is expected to accelerate Tempus's path to positive free cash flow and profitability.

Nancy Pelosi disclosed purchasing 50 TEM January 2026 $20 call options in mid-January, sparking retail interest. Simultaneously, Cathie Wood's ARK Invest boosted its stake by 132% (3.14 million shares) at the end of 2024, while Jane Street Group increased its position by 443%, Ken Griffin's Citadel Advisors bought 131,800 shares, and Balyasny Asset Management raised holdings by 515%. BlackRock also added 445,900 shares. While Tempus CFO Jim Rogers sold over 31,000 shares (worth ~$2.6 million), analysts view this as personal diversification rather than a bearish signal. TD Cowen maintains a buy rating with a $74 price target, and Tempus is scheduled to present at the TD Cowen Health Care Conference in early March. The stock, which fell from a high of $91.45 to $68, has rebounded 7% today as institutional conviction remains robust.